Thymoma Clinical Trial
Official title:
Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification. In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses. The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence. In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation. The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
| Completed |
NCT00332969 -
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
|
Phase 2 | |
| Completed |
NCT00921739 -
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
|
Phase 1 | |
| Recruiting |
NCT05255965 -
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
|
||
| Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
| Completed |
NCT00387868 -
Preoperative Treatment of Patients With High Risk Thymoma
|
Phase 2 | |
| Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A | |
| Recruiting |
NCT03466827 -
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
| Completed |
NCT02220855 -
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
|
Phase 2 | |
| Completed |
NCT03288662 -
Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
|
N/A | |
| Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
| Recruiting |
NCT06029621 -
Robot-assisted vs VATS for Thymoma
|
N/A | |
| Active, not recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
| Active, not recruiting |
NCT01621568 -
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
|
Phase 2 | |
| Recruiting |
NCT05262582 -
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy
|
N/A | |
| Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03968315 -
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
|
N/A | |
| Recruiting |
NCT04162691 -
Single Cell Sequencing Analysis of Thymoma
|
||
| Recruiting |
NCT06086327 -
Application of 68Ga-Pentixafor PET/CT for Thymoma
|
Early Phase 1 |